GlobeNewswire·Nov 9, 2026, 8:00 AM ET

Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026

MNPR

Monopar Therapeutics presented baseline data from the Phase 3 FoCus trial & long-term safety data for ALXN1840 at the AASLD Liver Meeting 2026 held Nov. 5–9, 2026.
Dr. Frederick K. Askari presented findings from the largest randomized controlled trial in Wilson disease showing high disease burden in both treatment-experienced & treatment-naïve patients.
Baseline cirrhosis rates were 39% in treatment-experienced patients & 30% in treatment-naïve patients, while neurologic symptoms affected 79% & 83% respectively.
Psychiatric symptoms were present in 75% of treatment-experienced patients & 70% of treatment-naïve patients at baseline.
73% of evaluable patients had at least two of the following conditions: cirrhosis, neurologic symptoms, or psychiatric symptoms.
47% of treatment-experienced patients were outside the guideline-recommended copper target range at baseline.
31% of patients on standard-of-care therapy for over 12 months had 24-hour urinary copper excretion above the recommended target range.
Professor Aftab Ala reported neutral molybdenum balance & no molybdenum toxicity with ALXN1840 over six years of treatment.
Serum uric acid levels remained within normal limits for subjects treated with ALXN1840 for six years.
ALXN1840 is a first-in-class albumin tripartite complex activator that mobilizes copper & demonstrated rapid, sustained copper mobilization superior to standard of care in the Phase 3 trial.
Monopar Therapeutics also has radiopharmaceutical programs in development for imaging & treating advanced cancers.

Company: Monopar Therapeutics Inc.
Keywords: Nasdaq:MNPR, Monopar Therapeutics Inc., MNPR, Monopar Therapeutics Inc, Monopar, AASLD, Wilson Disease